top of page
The Professional Network for Healthcare Experts
Slate Medicines to merge with Fulcrum Therapeutics and raise $245 million to advance migraine pipeline
The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.
nuaxia
12 hours ago3 min read
UK Biotech Financing Hits Five-Year High as Venture Capital Momentum Accelerates
Strong private investment signals renewed confidence in the UK life sciences sector, but public markets remain a challenge.
nuaxia
Jul 203 min read
bottom of page